balsalazide has been researched along with Colorectal Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Byeon, JS; Cho, EA; Chung, EJ; Do, EJ; Hwang, SW; Kim, JH; Kim, SY; Lee, HJ; Myung, SJ; Park, S; Park, SH; Ryu, YM; Yang, DH; Yang, SK; Ye, BD | 1 |
Jeong, HJ; Kim, EM; Kim, IH; Kim, SH; Kim, SL; Kim, SW; Kim, YN; Lee, SO; Lee, ST; Liu, YC; Park, YR; Seo, SY | 1 |
2 other study(ies) available for balsalazide and Colorectal Neoplasms
Article | Year |
---|---|
Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Azoxymethane; bcl-2-Associated X Protein; Cell Transformation, Neoplastic; Colitis; Colon; Colorectal Neoplasms; Dextran Sulfate; Disease Models, Animal; Gastrointestinal Agents; Inflammation Mediators; Interleukin-6; Macrophages; Male; Mesalamine; Mice, Inbred C57BL; Phenylhydrazines; Phosphorylation; Probiotics; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; STAT3 Transcription Factor; Time Factors | 2016 |
Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-κB Activation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinogenesis; Cell Proliferation; Colitis; Colorectal Neoplasms; Drug Synergism; Female; Humans; Mesalamine; Mice; Mice, Inbred BALB C; NF-kappa B; Phenylhydrazines; Sesquiterpenes; Signal Transduction | 2017 |